Scholarlink

Introduction <p>This real-world exploratory study in the United States (US) aimed to describe the socio-demographics, clinical characteristics, health-related quality of life (HRQoL), and work-related outcomes among people with obesity (PwO) undergoing a weight management program.</p> Methods <p>Secondary data from the US cohort of Adelphi Real World Obesity III Disease Specific Programme™ (October 2023 and April 2024, and October 2024 and January 2025) were analyzed. This cross-sectional survey included physicians and their consulting PwO without T2D who had a physician-confirmed diagnosis of obesity [body mass index (BMI) ≥ 30&#xa0;kg/m<sup>2</sup>] or overweight (BMI of ≥ 27&#xa0;kg/m<sup>2</sup> and &lt; 30&#xa0;kg/m<sup>2</sup>) with ≥ 1 obesity-related complication. Outcomes were summarized for three study groups based on a weight management approach at data capture: (1) tirzepatide group (received tirzepatide), (2) obesity management medication (OMM) group (received OMM excluding tirzepatide), and (3) non-OMM group (did not receive an OMM). Analyses were descriptive.</p> Results <p>The study included 1082 PwO (mean age: 47 years; female: 67.4%; tirzepatide: <i>n</i> = 199; OMM: <i>n</i> = 158; non-OMM: <i>n</i> = 725). The average time since OMM initiation was 7.4 months and 7.6 months for PwO in the tirzepatide and OMM groups, respectively. PwO in the tirzepatide group reported higher scores for most of the Short Form Health Survey version 2 (SF-36v2) domains than other groups; however, minimal differences were observed across all groups. A general trend towards greater work impairment among PwO in the non-OMM group than PwO in the tirzepatide and OMM groups was observed.</p> Conclusion <p>This real-world exploratory study in the US suggests that PwO taking tirzepatide reported less impairment in some of the SF-36v2 domains than those not on tirzepatide. PwO on tirzepatide or alternative OMM treatment appeared to have numerically lower impairment in work-related outcomes than those not on treatment. These findings warrant evaluation for long-term impact of tirzepatide and OMMs on work-related and HRQoL outcomes among PwO.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Health-Related Quality of Life and Work-Related Outcomes in People with Obesity or Overweight Treated with Tirzepatide or Other Obesity Medications: United States Results from the Adelphi Real World Obesity Disease Specific Programme™

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月11日

查看全文
  • Theresa Hunter Gibble,
  • Andrea Leith,
  • Lewis Harrison,
  • Claire Gerber,
  • Sonya Kokil Raikar,
  • Gayathri Ashok,
  • Esther Artime

摘要

Introduction

This real-world exploratory study in the United States (US) aimed to describe the socio-demographics, clinical characteristics, health-related quality of life (HRQoL), and work-related outcomes among people with obesity (PwO) undergoing a weight management program.

Methods

Secondary data from the US cohort of Adelphi Real World Obesity III Disease Specific Programme™ (October 2023 and April 2024, and October 2024 and January 2025) were analyzed. This cross-sectional survey included physicians and their consulting PwO without T2D who had a physician-confirmed diagnosis of obesity [body mass index (BMI) ≥ 30 kg/m2] or overweight (BMI of ≥ 27 kg/m2 and < 30 kg/m2) with ≥ 1 obesity-related complication. Outcomes were summarized for three study groups based on a weight management approach at data capture: (1) tirzepatide group (received tirzepatide), (2) obesity management medication (OMM) group (received OMM excluding tirzepatide), and (3) non-OMM group (did not receive an OMM). Analyses were descriptive.

Results

The study included 1082 PwO (mean age: 47 years; female: 67.4%; tirzepatide: n = 199; OMM: n = 158; non-OMM: n = 725). The average time since OMM initiation was 7.4 months and 7.6 months for PwO in the tirzepatide and OMM groups, respectively. PwO in the tirzepatide group reported higher scores for most of the Short Form Health Survey version 2 (SF-36v2) domains than other groups; however, minimal differences were observed across all groups. A general trend towards greater work impairment among PwO in the non-OMM group than PwO in the tirzepatide and OMM groups was observed.

Conclusion

This real-world exploratory study in the US suggests that PwO taking tirzepatide reported less impairment in some of the SF-36v2 domains than those not on tirzepatide. PwO on tirzepatide or alternative OMM treatment appeared to have numerically lower impairment in work-related outcomes than those not on treatment. These findings warrant evaluation for long-term impact of tirzepatide and OMMs on work-related and HRQoL outcomes among PwO.